Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Neumora Therapeutics, Inc. (NMRA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
07:30am, Friday, 24'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA
Neumora Therapeutics, Inc. (NMRA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
07:25am, Thursday, 23'rd Jan 2025
NEW YORK, NY / ACCESSWIRE / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA) con
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA
Neumora Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NMRA
11:00am, Monday, 20'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ
Neumora Stock Hits Record Low on Depression Drug Study Failure
10:20am, Friday, 03'rd Jan 2025
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
06:40pm, Thursday, 02'nd Jan 2025
LOS ANGELES--(BUSINESS WIRE)--Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA.
Neumora's depression drug fails trial, sinking shares
03:15pm, Thursday, 02'nd Jan 2025
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints
11:19am, Thursday, 02'nd Jan 2025
Neumora Therapeutics shares tumbled over 83% on Thursday after its experimental drug for major depressive disorder (MDD), navacaprant, failed to demonstrate significant benefits in the pivotal Phase 3
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
10:55am, Thursday, 02'nd Jan 2025
Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet i
Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals
10:27am, Thursday, 02'nd Jan 2025
News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
09:00am, Thursday, 02'nd Jan 2025
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three studies. The post Neumora Therapeutics Stock Crashes 83% After Depression Drug Fl
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
07:18am, Thursday, 02'nd Jan 2025
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
07:00am, Thursday, 02'nd Jan 2025
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo
Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
01:11pm, Tuesday, 24'th Dec 2024
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed signifi
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
11:03am, Wednesday, 13'th Nov 2024
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for majo
